DDIT3 and colorectal carcinoma: Our results demonstrated that the intense ERS displayed potent anti-CRC effect partly by sensitizing CRC cells to Oxaliplatin via down-regulating ABCC10 through IRE1α RIDD activity, in addition to increasing pro-apoptotic factor CHOP (Fig. 7).